EyePoint Pharmaceuticals Inc (EYPT)

[bernice]

ladenburg-thalmann-financial-services-analysts-give-psivida-corp-psdv-a-13-00-price-target

Ladenburg Thalmann Financial Services Analysts Give pSivida Corp. (PSDV) a $13.00 Price Target
June 15th, 2017 • 0 comments • Filed Under • by ABMN Staff

inShare
pSivida Corp. logopSivida Corp. (NASDAQ:PSDV) received a $13.00 target price from investment analysts at Ladenburg Thalmann Financial Services in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the stock.

PSDV has been the topic of several other reports. HC Wainwright set a $8.00 target price on pSivida Corp. and gave the stock a “buy” rating in a report on Wednesday. FBR & Co reaffirmed a “buy” rating on shares of pSivida Corp. in a report on Wednesday. Rodman & Renshaw assumed coverage on pSivida Corp. in a report on Tuesday, May 30th. They issued a “buy” rating and a $8.00 target price on the stock. Finally, Northland Securities set a $10.00 target price on pSivida Corp. and gave the stock a “buy” rating in a report on Wednesday. Five research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $9.20.

Get pSivida Corp. alerts:
Enter Your Email Address
Submit
Analyst Recommendations for pSivida Corp. (NASDAQ:PSDV)

pSivida Corp. (PSDV) traded up 1.7543% during midday trading on Wednesday, reaching $1.7807. 1,738,229 shares of the company were exchanged. The firm’s 50-day moving average is $2.02 and its 200-day moving average is $1.83. The firm’s market cap is $69.92 million. pSivida Corp. has a one year low of $1.50 and a one year high of $4.25.



pSivida Corp. (NASDAQ:PSDV) last issued its earnings results on Thursday, May 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.15). pSivida Corp. had a negative return on equity of 119.87% and a negative net margin of 262.62%. The firm had revenue of $0.59 million for the quarter, compared to analysts’ expectations of $0.36 million. On average, equities analysts expect that pSivida Corp. will post ($0.51) EPS for the current fiscal year.

In other news, insider Nancy Lurker bought 56,700 shares of pSivida Corp. stock in a transaction dated Wednesday, June 14th. The shares were purchased at an average cost of $1.76 per share, with a total value of $99,792.00. Following the completion of the acquisition, the insider now owns 56,700 shares of the company’s stock, valued at approximately $99,792. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 2.59% of the company’s stock.

A number of large investors have recently modified their holdings of PSDV. Geode Capital Management LLC boosted its stake in shares of pSivida Corp. by 0.5% in the first quarter. Geode Capital Management LLC now owns 143,049 shares of the company’s stock valued at $246,000 after buying an additional 756 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of pSivida Corp. by 34.0% in the fourth quarter. Renaissance Technologies LLC now owns 907,000 shares of the company’s stock valued at $1,551,000 after buying an additional 229,900 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of pSivida Corp. by 3.5% in the first quarter. Vanguard Group Inc. now owns 1,145,802 shares of the company’s stock valued at $1,971,000 after buying an additional 38,897 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new stake in shares of pSivida Corp. during the fourth quarter valued at $3,898,000. 20.02% of the stock is currently owned by institutional investors.

About pSivida Corp.

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.